The data being submitted includes GWAS for 4,496 participants from the Knight-ADRC MAP study.  Participants include 1,958 AD cases (58% Females, 56% APOE4+, average age 73), 755 ADRD cases (FTD, DLB, PD, PSP, ALS, other: 51% Females, 38% APOE4+, average age 73), and 1,783 cognitively healthy controls (60% Females, 31% APOE4+, average age 74).  Approximately 86% of the samples are self-defined as “White” and 12.5% are self-defined as “Black or African-American”.  Genotyping was generated through 10 different genotyping arrays (Infinium CoreExome-24, Infinium Neuro Consortium Array, Infinium Global Screening Array-24, Infinium OmniExpress-24, Illumina Human660W-Quad, Human610-Quad, Illumina Omni1-Quad, Affy UK Biobank Axiom, Infinium OmniExpressExome-8, and Illumina Human1M-Duo).   All genotype samples have polygenic risk scores indicating the risk for Alzheimer’s disease (AD), Parkinson’s disease (PD), Frontotemporal dementia (FTD) risk along with CSF Aβ42, phosphorylated tau, and total tau.